Pyrotinib, Trastuzumab, Pertuzumab and Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer
Status:
Recruiting
Trial end date:
2027-12-30
Target enrollment:
Participant gender:
Summary
This study aims to evaluate the efficacy and safety of pyrotinib in combination with
trastuzumab, pertuzumab and nab-paclitaxel as neoadjuvant therapy in early stage or locally
advanced HER2-positive breast cancer.